Simple blood test may predict muscle disease severity
NCT ID NCT07415837
First seen Mar 01, 2026 · Last updated Jun 22, 2026 · Updated 15 times
Summary
This study is looking at whether a molecule in the blood called miR-1 can help doctors understand how muscle diseases like Duchenne muscular dystrophy and myotonic dystrophy are progressing. Researchers will compare miR-1 levels in 104 people, including patients with different muscle conditions and healthy volunteers. The goal is to see if miR-1 levels match how severe the disease is, which could lead to a simple blood test for monitoring these conditions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY PARTICIPANTS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
CHU de Clermont-Ferrand
RECRUITINGClermont-Ferrand, France
Contact
Contact Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
What this could lead to
If successful, this could lead to a simple blood test to monitor muscle disease progression, helping doctors adjust treatments earlier.
What could go wrong
This is an early observational study, not a treatment trial. It may find that miR-1 levels do not reliably reflect disease severity, or results may not apply to all muscle conditions.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.